lava-051
lava therapeutics
['cll', 'multiplemyeloma', 'lava-051 ', 'lava-051', 'lava therap']
today, 5:30pm ct, at #ash22, arnon kater, md, phd, will present updated phase 1 clinical trial data from our cd1d-targeting bispecific #gammadelta t-cell engager, lava-051, in patients with #cll &amp; #multiplemyeloma. read the press release: #immunooncology 
Immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to treat cancer.